The USP Beal Award for Distinguished Volunteer Service recognizes a person who has made outstanding contributions to the public health while serving as a USP volunteer. It was created to honor the lifelong USP contributions of James Hartley Beal, Ph.D., LL.B. (1861–1945) and his son, George Denton Beal, Ph.D. (1888–1972). The Beal Award is bestowed every five years at the USP Convention's Membership Meeting.
The Beals promoted public health through their voluntary service to USP for a combined total of nearly 80 years. James Hartley Beal, former dean of the Scio (Ohio) College of Pharmacy, began his involvement with USP as a Convention member in 1900 and served as chairman of the Board of Trustees from 1910 to 1940. He was instrumental in gaining recognition for USP in the Pure Food and Drugs Act of 1906 and retaining that recognition in the 1938 Food, Drug, and Cosmetic Act. George Denton Beal, former director of research for the Mellon Institute in Pittsburgh, was instrumental in establishing USP's Reference Standards program. He served on the Committee of Revision (the predecessor to the Council of Experts) from 1930 to 1954 and as chairman of the Board from 1954 to 1968.
Beal Award Recipients
Ms. Davidson was elected as chair of the Compounding Expert Committee and in that position played a major leadership role in USP’s response to several public health crises involving contaminated compounded preparations. During her tenure, Ms. Davidson was actively engaged in multiple expert committees, advisory panels and industry forums and oversaw the development of well in excess of 30 new compounded preparation monographs. She also spearheaded the development of the USP on Compounding: A Guide for the Compounding Practitioner which became the USP Compounding Compendium, USP’s newest publication – a collection of essential compounding standards for use or consideration by practitioners and regulatory authorities alike.
Under her leadership, the Compounding Expert Committee won the 2012-2013 USP Award for an Outstanding Contribution to the Standard-Setting Process in recognition of its response to the compounding crises and its impact on improving public health.
Ms. Davidson is the director of Clinical Pharmacy Services at the North Carolina State University College of Veterinary Medicine, a Clinical Associate Professor of Pharmacy at Wingate University School of Pharmacy, a Clinical Associate Professor of Pharmacy and Therapeutics at Pittsburgh School of Pharmacy, a Clinical Associate Professor of Pharmacy Practice at Virginia Commonwealth University School of Pharmacy, a Clinical Associate Professor of Pharmacy Practice at Findlay University College of Pharmacy, a Clinical Associate Professor of Pharmacy Practice at East Tennessee State University’s Gatton College of Pharmacy, and a Visiting Scholar at the University of North Carolina Eshelman School of Pharmacy.
Ms. Davidson also sits on multiple boards including the American College of Veterinary Pharmacists, the Pharmacy Compounding Accreditation Board Standards Committee and has served on FDA’s Task Force on Compounding in Veterinary Medicine as well as the FDA/AVMA Ad Hoc Committee on Veterinary Compounding.
Dr. Foster's involvement with USP spanned nearly two decades with myriad contributions. From 1990 to 1995, he served on the FDA–USP Joint Committee on Bioequivalence and the Subcommittee on Bioavailability, Bioequivalence, and Dissolution (DBA). Dr. Foster was elected chairman of the DBA in 1995, which was re-named the Biopharmaceutics Expert Committee in 2000. From 2000 to 2005, he also served on the Reference Standards Expert Committee, the General Policies and Requirements Executive Committee, and the Medicare Model Guidelines Expert Committee. He was a member of the Nomenclature and Labeling Expert Committee since 2000. Dr. Foster was instrumental in the development and revision of many USP General Chapters on topics including bioequivalence, dissolution, and drug dosage forms. He championed the science and public standard setting processes related to in-vitro and in-vivo drug performance and was instrumental in developing a compendial taxonomy for pharmaceutical dosage forms. In addition to his scientific and clinical committee work, Dr. Foster served as Vice Chair of three separate Nominating Committees for the Council of Experts from 2000 to 2010.
Dr. Foster was a Professor in the Colleges of Pharmacy, Medicine, and Public Health at the University of Kentucky (UK). Since 1973, he practiced in the University Hospital and Clinics; taught professional and graduate courses in advanced pharmacotherapy, pharmacokinetics / pharmacodynamics, computer and information systems and bioethics and research integrity; and he led programs in multidisciplinary clinical pharmacology research involving investigational drugs and drug delivery systems. He pioneered the opening and served as director for both a multidisciplinary Drug Product Evaluation Unit at the UK Medical Center and the Center of Excellence in Pharmaceutical Science and Technology at UK, the first academic center based, FDA cGMP qualified facility for pilot parenteral drug manufacturing. Dr. Foster's pioneer work in translational science facilitated the development of numerous human pharmaceutical and biopharmaceutical products and drug delivery systems. He served as the Director of the Regulatory Support and Research Integrity program of the UK Center for Clinical and Translational Science and was the Executive Chairman of the University's Medical Institutional Review Boards since 1987. He was a consultant to the FDA Center for Drug Evaluation and Research and the Department Health and Human Services Office of Human Research Protections.
Since 1970, Dr. Herbert Carlin has chaired more than 35 USP committees and panels. From 2000 to 2005, he served in the following positions: chair of the Nomenclature and Labeling Expert Committee; member of the General Policies and Requirements Division Executive Committee; member of the Information Division Executive Committee; member of the Nominating Committee for the Council of Experts; member of the Ad Hoc Committee on Taxonomy; and member of the Ad Hoc Committee on Standardized Imprint Codes for Solid Oral Dosage Forms. In 2000, Dr. Carlin became an Honorary Member of the USP Convention in recognition of his efforts as a member of the Committee of Revision (the predecessor group to the Council of Experts), as chair of the Nomenclature Committee since 1985, and for his long-standing commitment to USP. Beyond his scientific service, Dr. Carlin has been a member of the USP Convention in five separate cycles. He was also a member of the Nominating Committee for the 2005–2010 Council of Experts.
Dr. Lester Chafetz worked to improve drug quality through 35 years of outstanding voluntary service on the Committee of Revision (the predecessor to the Council of Experts). He contributed significantly to many areas of standards setting, including drug substances, natural products, separation science and the chromatography of dosage forms, and packaging and stability. His distinguished career in industrial pharmaceutical analysis and research, capped by a university professorship involving both teaching and a research program, spans over 40 years.
2000 - Ralph F. Shangraw, Ph.D. (Inaugural Recipient)
The late Dr. Ralph Shangraw had a profound impact on public standards through his service on the USP Committee of Revision (the predecessor to the Council of Experts) from 1970 to 1998. He promoted modern standards for excipients that are recognized worldwide. He improved the multivitamin and mineral marketplace by pioneering the establishment of USP standards in this field. He always championed the cause of patients and consumers. His efforts led to public standards for combination cough-cold preparations and other over-the-counter drug products.